In This Article:
RMTG Reports Huge Sales Increases and Continued Positive Operating Income
LAS VEGAS, NEVADA / ACCESS Newswire / April 16, 2025 / Regenerative Medical Technologies Group, Inc. (the "Company" or "RMTG"), a regenerative medicine company, is pleased to announce that it closed its 2024 fiscal year with approximately $4.1 million in sales, a more than 70% increase over 2023 levels and achieved positive operating income for all of 2024 (defined below). The Company also increased Q4 sales of this year by 146% compared to Q4 sales of last year.
For fiscal 2024, the company only increased total operating expenses by 15% compared to the 70% increase in revenues and maintained gross margins of approximately 69% for both years, which points to the Company's accretive growth in overall operating income.
As well, Q4 sales for 2024 grew by over 50% compared to Q3 sales for 2024.
Sales were derived from the Company's 4 main revenue channels, Product sales, Equipment sales, Patient procedures, and Training.
"We are very happy with this year's performance and of reaching the very significant milestone of positive operating income, we expect to continue to grow revenues in our four main lines of business and increase operating income," said David Christensen CEO/President of the Company.
"This past year has been pivotal for us as we ramped up operations in our Cancun clinic and the coming year should prove even more significant for us as we move to increase sales and make future announcements about revenue generating buildouts," said Benito Novas, CEO/Founder Global Stem Cells Group.
Operating income is a GAAP measure calculated herein as revenue minus the cost of goods sold and operating expenses, excluding non-operating items such as interest and taxes.
This press release should be read in conjunction with all of the company's filings on www.sec.gov
About Regenerative Medical Technology Group
Regen Med Tech Group is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary Global Stem Cells Group (GSCG). GSCG is an innovative provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative patient therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, GSCG is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare. The Company also distributes stem cells and other regenerative based cell lines, and equipment internationally and likewise specializes in education and training physicians in the area of regenerative medicine.